Every moment counts when treating a patient with a heart attack since early action is crucial to preserve heart muscle. The longer a coronary artery is closed, the more severe the damage to the heart. We’re developing zalunfiban, a prompt, potent, and predictable medication that can be given before a patient reaches the hospital, saving crucial time in treating a heart attack.
To Get More Heart Attack Patients to the Hospital with Open Coronary Arteries
Each year, 800,000 people in the U.S. have a heart attack, a life-threatening condition in which blood flow to the heart muscle is suddenly decreased or blocked by a blood clot in one or more of the coronary arteries.
While management of heart attacks has significantly improved, morbidity and death from heart attacks remain high.
It often takes more than an hour to transport a heart attack patient—and at least 50% of heart attack deaths occur before the patient reaches the hospital.
Yet there is no treatment routinely used in the U.S. to treat heart attacks in the pre-hospital setting other than aspirin.
For all these reasons, there is a need for a prompt, potent, and predictable medication that can be given before a patient reaches the hospital. Zalunfiban has the potential to meet that need.
In the initial stages of a heart attack, platelet aggregation (clumping) occurs at sites of injury in a coronary artery, resulting in blood clot formation in the coronary artery—a process in which the platelet GPIIb/IIIa receptor plays a key role.
A fast-acting GPIIb/IIIa receptor antagonist could reduce blood clot formation in the coronary artery or lead to opening of the coronary artery.
Zalunfiban is a next-generation GPIIb/IIIa platelet inhibitor that was specifically designed for pre-hospital treatment of heart attacks and is injected under the skin.
Zalunfiban reaches maximal effect within 15 minutes and its antiplatelet effect wears off in less than two hours, which may reduce the risk of bleeding and avoid interfering with later patient treatment.
While other available platelet inhibitors only block specific activators (e.g., P2Y12 inhibitors only inhibit ADP), zalunfiban can block platelet aggregation induced by all platelet activators, including thrombin.Read More
CeleBrate, a pivotal Phase 3 prospective, blinded, randomized, placebo-controlled, international multicenter study, is designed to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in patients with ST-segment elevation myocardial infarction in the pre-hospital setting. To learn more, visit ClinicalTrials.gov.Learn More
Completion of our pivotal CeleBrate Phase 3 clinical trial in a pre-hospital setting to support a marketing application.
Market expansion into additional indications as data warrant, including the potential for approval of a self-administered drug product.